Manufacturing process development strategies for high concentration biologic drug products: from downstream...

There is a growing demand for high-concentration protein formulations (HCPFs), driven by certain therapeutics that require high doses and the volume limitations of subcutaneous administration. However, downstream processing and fill-finish for these HCPFs plays a critical role and remains a major limitation. It accounts for nearly 60% of the total production cost and faces significant challenges in scalability and efficiency. These challenges are largely attributed to inherent complexity, which involve multiple unit operations such as ultrafiltration, bulk drug substance freezing, thawing, mixing, sterile filtration and drug product fill-finish. This review provides a comprehensive overview of downstream processing and fill-finish for high-concentration protein formulations, highlighting the key challenges, particularly related to drug stability, (such as protein aggregation, or particulate formation), viscosity and solubility (such as turbidity or phase separation). Addressing these multifactorial challenges demands various strategies that include formulation and process optimization, and the use of specialized delivery systems which are discussed herewith. Moreover, emerging trends such as process analytical technologies (PAT), use of non-aqueous delivery vehicles and potential of using solid suspensions are also highlighted as promising strategies for overcoming the current limitations. Finally, to address the real-world applications, case studies of two FDA-approved high-concentration formulations (up to 200 mg/mL) are presented illustrating the need for formulation and process design for enabling successful clinical translation.